N-Acetyl Cystein and Contrast Nephropathy
Launched by IMAM KHOMEINI HOSPITAL · Mar 27, 2013
Trial Information
Current as of May 14, 2025
Unknown status
Keywords
ClinConnect Summary
Contrast Nephropathy is the third cause of acute kidney injury in hospitalized patients. The morbidity and mortality of this disorder is considerable. There is no treatment for this condition and all measures should be taken into account to prevent this complication. Among the all prophylactic measures hydration and the dose ant type of contrast are the only factors that have been proved to be effective in preventing contrast nephropathy. N-Acetyl Cystein is an antioxidant agents that may be effective in different aspects of medicine, but it,s use in this condition is controversial. While s...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age more than 18
- • chronic Kidney disease stage 2-4
- • use of nephrotoxins in last week leading to angiography
- Exclusion Criteria:
- • Acute kidney injury
- • concomitant use of other nephrotoxins
- • need of repeated imaging with contrast in five days after the first surgery
- • need for surgery in next five day after the contrast exposure
- • need of using nephrotoxins in next five days after contrast exposure
About Imam Khomeini Hospital
Imam Khomeini Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. With a commitment to excellence, the hospital collaborates with a multidisciplinary team of experienced healthcare professionals and researchers to conduct rigorous studies across various therapeutic areas. By prioritizing patient safety and ethical standards, Imam Khomeini Hospital aims to contribute valuable insights to the medical community and enhance treatment options for diverse populations. Its state-of-the-art facilities and comprehensive approach to clinical research position it as a pivotal player in the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tehran, , Iran, Islamic Republic Of
Patients applied
Trial Officials
Mohammad R Khatami, MD
Study Chair
Nephrology Research Center
Ebrahin Kassaian, MD
Principal Investigator
Tehran Heart Center
Mojtaba Salarifar, MD
Principal Investigator
Tehran Heart Center
Ali Kazemi-Saeid, MD
Principal Investigator
Tehran Heart Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials